Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Skin Neoplasms 1Recurrence 1Neoplasms 1Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Lymphocytic, Chronic, B-Cell 1Gliosarcoma 1Glioblastoma 1Carcinoma, Basal Cell 1

Interventions

Temozolomide 85Radiotherapy 51Bevacizumab 31Irinotecan 19Radiation 16Carmustine 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14O(6)-benzylguanine 11Chemotherapy, Adjuvant 11Carboplatin 9sargramostim 8Thalidomide 8Imatinib Mesylate 8Filgrastim 8Surgical Procedures, Operative 6Gene Expression Profiling 6Drug Therapy 6pembrolizumab 5aldesleukin 5Topotecan 5Radiotherapy, Intensity-Modulated 5Hydroxyurea 5Gefitinib 5Etoposide 5Sorafenib 4Immunohistochemistry 4Dasatinib 4Celecoxib 4Biopsy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gliosarcoma × Dimethyl Fumarate × Clear all
NCT02337426 2019-06-28

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Virginia Commonwealth University

Phase 1 Completed
12 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡